Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.

Oswaldo Castaneda, M Gopal Nair

Journal: The Journal of rheumatology 2006;33(5):862-4

PMID: 16652417

Abstract

OBJECTIVE

To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA).

METHODS

A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA.

RESULTS

Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504.

CONCLUSION

CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.

Address: Universidad Peruana Cayetano Heredia, Lima, Peru.

Link outs

Free resources

Medical:

https://medlineplus.gov/rheumatoidarthritis.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

http://www.jrheum.org/lookup/pmidlookup?view=long&...

MeSH Terms: Adult, Aged, Aminopterin, Antirheumatic Agents, Arthritis, Rheumatoid, Female, Folic Acid Antagonists, Gastrointestinal Tract, Humans, Liver, Liver Function Tests, Male, Methotrexate, Middle Aged